Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: A Southern Italy Cooperative Oncology Group phase II study

P. Comella, B. Massidda, S. Palmeri, A. Farris, L. De Lucia, D. Natale, L. Maiorino, S. Tafuto, G. De Cataldis, R. Casaretti

Research output: Contribution to journalArticlepeer-review

Abstract

Oxaliplatin 100 mg/m2 iv on day 1, and capecitabine 1,000 mg/m2 orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma. A total of 318 cycles were administered, with a median of 8 (range, 4-12) cycles per patient. Response rate (RR) was 45% (95% confidence interval (CI), 29%-62%), with 7 complete responses and 10 partial responses; furthermore, 12 patients showed a stable disease, so that a disease control was achieved in 29 (76%) patients. RR was greater among patients with performance status 0 (52%), without weight loss (52%), younger than 65 years (50%), and previously unexposed to adjuvant chemotherapy (48%), while no correlation was found with the actually delivered oxaliplatin dose intensity. Overall, haematological side effects were negligible, with no case of grade 4 toxicity, and only one patient suffering from an episode of grade 3 neutropenic fever. Severe anaemia occurred in 4 (11%) patients, and grade 3 neuropathy affected 9 (24%) patients. Median progression-free survival was 7.9 (95% CI, 6.2-9.6) months, and median overall survival has not been reached yet. In conclusion, the OXXEL regimen resulted safe and active, and it deserves further evaluation in metastatic colorectal cancer patients.

Original languageEnglish
Pages (from-to)481-486
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume56
Issue number5
DOIs
Publication statusPublished - Nov 2005

Keywords

  • Biweekly treatment
  • Capecitabine
  • Metastatic colorectal cancer
  • Oxaliplatin
  • OXXEL regimen

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Fingerprint Dive into the research topics of 'Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: A Southern Italy Cooperative Oncology Group phase II study'. Together they form a unique fingerprint.

Cite this